AR069611A1 - Sal tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma - Google Patents
Sal tosilato de un compuesto terapeutico y composiciones farmaceuticas de la mismaInfo
- Publication number
- AR069611A1 AR069611A1 ARP080105336A ARP080105336A AR069611A1 AR 069611 A1 AR069611 A1 AR 069611A1 AR P080105336 A ARP080105336 A AR P080105336A AR P080105336 A ARP080105336 A AR P080105336A AR 069611 A1 AR069611 A1 AR 069611A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorders
- congestion
- pharmaceutical compositions
- same
- allergy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229950004288 tosilate Drugs 0.000 title 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 2
- 230000007815 allergy Effects 0.000 abstract 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 2
- 208000027744 congestion Diseases 0.000 abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 2
- 125000005490 tosylate group Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 206010028735 Nasal congestion Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 230000009858 acid secretion Effects 0.000 abstract 1
- 230000008369 airway response Effects 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000002173 dizziness Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000036543 hypotension Effects 0.000 abstract 1
- 201000003152 motion sickness Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US569607P | 2007-12-07 | 2007-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069611A1 true AR069611A1 (es) | 2010-02-03 |
Family
ID=40380628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105336A AR069611A1 (es) | 2007-12-07 | 2008-12-09 | Sal tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8178574B2 (https=) |
| EP (1) | EP2231630B1 (https=) |
| JP (1) | JP4566259B2 (https=) |
| KR (1) | KR20100075679A (https=) |
| CN (1) | CN101939306A (https=) |
| AR (1) | AR069611A1 (https=) |
| AU (1) | AU2008332880C1 (https=) |
| CA (1) | CA2708043C (https=) |
| IL (1) | IL205963A0 (https=) |
| MX (1) | MX2010006162A (https=) |
| NZ (1) | NZ585671A (https=) |
| RU (1) | RU2451016C2 (https=) |
| TW (1) | TW200932213A (https=) |
| WO (1) | WO2009071988A1 (https=) |
| ZA (1) | ZA201004768B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2124933B1 (en) | 2007-01-22 | 2012-10-17 | Pfizer Products Inc. | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| AR103406A1 (es) * | 2015-01-30 | 2017-05-10 | Lilly Co Eli | Sal de tosilato |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5498626A (en) * | 1992-04-10 | 1996-03-12 | Pfizer Inc. | Acylaminoindole derivatives as 5-ht1 agonists |
| US8158673B2 (en) * | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| EP2124933B1 (en) * | 2007-01-22 | 2012-10-17 | Pfizer Products Inc. | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
-
2008
- 2008-12-04 CN CN2008801264902A patent/CN101939306A/zh active Pending
- 2008-12-04 KR KR1020107012321A patent/KR20100075679A/ko not_active Abandoned
- 2008-12-04 MX MX2010006162A patent/MX2010006162A/es not_active Application Discontinuation
- 2008-12-04 RU RU2010122972/04A patent/RU2451016C2/ru not_active IP Right Cessation
- 2008-12-04 NZ NZ585671A patent/NZ585671A/en not_active IP Right Cessation
- 2008-12-04 AU AU2008332880A patent/AU2008332880C1/en not_active Ceased
- 2008-12-04 CA CA2708043A patent/CA2708043C/en not_active Expired - Fee Related
- 2008-12-04 US US12/745,982 patent/US8178574B2/en not_active Expired - Fee Related
- 2008-12-04 EP EP08858146A patent/EP2231630B1/en not_active Not-in-force
- 2008-12-04 WO PCT/IB2008/003392 patent/WO2009071988A1/en not_active Ceased
- 2008-12-05 JP JP2008310400A patent/JP4566259B2/ja not_active Expired - Fee Related
- 2008-12-05 TW TW097147550A patent/TW200932213A/zh unknown
- 2008-12-09 AR ARP080105336A patent/AR069611A1/es not_active Application Discontinuation
-
2010
- 2010-05-25 IL IL205963A patent/IL205963A0/en unknown
- 2010-07-06 ZA ZA2010/04768A patent/ZA201004768B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL205963A0 (en) | 2010-11-30 |
| NZ585671A (en) | 2012-06-29 |
| CA2708043A1 (en) | 2009-06-11 |
| RU2010122972A (ru) | 2011-12-10 |
| WO2009071988A1 (en) | 2009-06-11 |
| AU2008332880C1 (en) | 2012-07-19 |
| EP2231630B1 (en) | 2012-11-07 |
| KR20100075679A (ko) | 2010-07-02 |
| CN101939306A (zh) | 2011-01-05 |
| JP2009161517A (ja) | 2009-07-23 |
| CA2708043C (en) | 2012-11-13 |
| ZA201004768B (en) | 2011-03-30 |
| AU2008332880A1 (en) | 2009-06-11 |
| AU2008332880B2 (en) | 2012-01-19 |
| TW200932213A (en) | 2009-08-01 |
| JP4566259B2 (ja) | 2010-10-20 |
| US20100256213A1 (en) | 2010-10-07 |
| US8178574B2 (en) | 2012-05-15 |
| MX2010006162A (es) | 2010-06-25 |
| RU2451016C2 (ru) | 2012-05-20 |
| EP2231630A1 (en) | 2010-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064963A1 (es) | Sal de tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma | |
| UY29882A1 (es) | Antagonistas del receptor 3 de la histamina | |
| DE602006018301D1 (de) | Histamin-3-rezeptorantagonisten | |
| WO2007105053A3 (en) | Tetralines antagonists of the h-3 receptor | |
| WO2007088450A3 (en) | Chromane antagonist of the h-3 receptor | |
| EA201100423A1 (ru) | Новые бензамиды, их получение и их применение в качестве лекарственных средств | |
| EP2282795A4 (en) | TREATMENT OF RESPIRATORY DISEASES | |
| BRPI0507374A (pt) | moduladores do receptor de histamina-3 | |
| NI200700084A (es) | Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento del trastorno de ansiedad generalizada | |
| IL216468B (en) | Pharmaceutical compositions deliverable from a metered dose inhaler comprising glycopyrrolate and formoterol and their use in treatment of pulmonary diseases | |
| DOP2012000167A (es) | Moduladores alostericos positivos de receptores m1 de la quinolina amida | |
| AR069611A1 (es) | Sal tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma | |
| JP7575099B2 (ja) | 呼吸器疾患の処理のための新規な化合物 | |
| CO6410283A2 (es) | Métodos para administrar (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a través de la mucosa oral, la mucosa nasal o la piel, y sus compoisiciones farmacéuticas | |
| ATE479433T1 (de) | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel | |
| CY1113996T1 (el) | Trans-4-{2-[4-(2,3-διχλωροφαινυλ)-πιπεραζιν-1-υλ]-αιθυλ}-ν,ν-διμεθυλκαρβαμοϋλ-κυκλοεξυλαμινη για θεραπεια σχιζοφρeνειας | |
| AR065477A1 (es) | Diaminopirimidinas | |
| GB0620385D0 (en) | Novel compounds | |
| BR112013031759A2 (pt) | forma cristalina de derivados de indazolil amida para o tratamento de distúrbios mediados pelo receptor de glicocorticoides | |
| BRPI0516079A (pt) | antagonistas de receptor de histamina-3 | |
| CY1113762T1 (el) | Τοσυλικο αλας μιας θεραπευτικης ενωσης και φαρμακευτικες συνθεσεις αυτου | |
| BRPI0514820A (pt) | antagonistas de receptor de histamina-3 amina azabicìclicos | |
| EA201070336A1 (ru) | Ингаляционный азтреонам лизин для лечения нарушений, снижающих качество жизни, обусловленное состоянием здоровья при заболеваниях легких | |
| CY1114789T1 (el) | Ανταγωνιστες υποδοχεα ισταμινης-3 | |
| CU20070070A7 (es) | Composición farmacéutica de agomelatina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |